Unió Europea - portuguès - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unió Europea - portuguès - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - esclerose múltipla - imunossupressores seletivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unió Europea - portuguès - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Unió Europea - portuguès - EMA (European Medicines Agency)

ucb pharma s.a. - rotigotina - restless legs syndrome; parkinson disease - anti-parkinson - doença de parkinson: neupro está indicado para o tratamento dos sinais e sintomas de doença de parkinson idiopática em estágio inicial como monoterapia (i. sem levodopa) ou em combinação com levodopa, i. ao longo da doença, até os estágios tardios quando o efeito da levodopa desaparecer ou se torna inconsistente e as flutuações do efeito terapêutico ocorrem (fim da dose ou flutuações "on-off"). síndroma das pernas inquietas: neupro é indicado para o tratamento sintomático de moderada a grave idiopática síndroma das pernas inquietas em adultos.

Unió Europea - portuguès - EMA (European Medicines Agency)

roche registration gmbh - cloridrato de alectinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - alecensa como monoterapia é indicada para o tratamento de primeira linha de pacientes adultos com linfoma quinase anaplásico (alk) - câncer de pulmão avançado não-pequeno de células pequenas (nsclc). alecensa como monoterapia é indicado para o tratamento de pacientes adultos com alk‑positivo avançada nsclc previamente tratados com crizotinib.

Portugal - portuguès - DGAV (Direção Geral de Alimentação e Veterinária)

propet, lda. - solução - caninos; felinos

Unió Europea - portuguès - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Unió Europea - portuguès - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Unió Europea - portuguès - EMA (European Medicines Agency)

amgen europe bv - sotorasib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Unió Europea - portuguès - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoma, pulmão de células não pequenas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.